Peptide Comparison
Sermorelin vs CJC-1295 + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Sermorelin | CJC-1295 + Ipamorelin | |
|---|---|---|
| Class | GHRH analog | GHRH analog + selective GHRP blend (GH-secretagogue stack) |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release | Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). |
| Route | SC injection | SC injection |
| Half-life | ~10-20 min | CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs |
| Dosage (research) | 200-500 mcg SC at bedtime daily | 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off |
| Evidence tier | Discontinued (FDA approval 1990; US withdrawal 2008) | Anecdotal + Animal Studies |
| Research depth | 149 indexed | 5 indexed |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Injection site reactions; headache; flushing | Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Sermorelin or CJC-1295 + Ipamorelin?
Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Sermorelin and CJC-1295 + Ipamorelin?
Sermorelin is classed as GHRH analog; CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: Sermorelin, ~10-20 min; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: Sermorelin, SC injection; CJC-1295 + Ipamorelin, SC injection.
Which has stronger evidence, Sermorelin or CJC-1295 + Ipamorelin?
Sermorelin and CJC-1295 + Ipamorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.
Which is more accessible, Sermorelin or CJC-1295 + Ipamorelin?
Neither Sermorelin nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: Sermorelin, Compounding Restricted; CJC-1295 + Ipamorelin, Compounding Restricted.
Are Sermorelin and CJC-1295 + Ipamorelin ever combined?
Sermorelin and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…